Cardiology

Top Medical News
Stroke up 30 percent since 2001 in HK’s ≤55-year-olds
Natalia Reoutova, Yesterday

Researchers from the University of Hong Kong (HKU) report that the incidence of “young stroke” (ie, strokes occurring in those aged 18–55 years) has increased by 30 percent in Hong Kong’s residents since 2001.

Dose reduction needed in HFrEF patients on sacubitril-valsartan
Yesterday
Some patients with heart failure with reduced ejection fraction (HFrEF) need a loop diuretic dose reduction within 2‒3 months following initiation of sacubitril-valsartan, suggests a study.
Adding salt to foods ups CVD risk
2 days ago
The addition of salt to foods appears to increase the risk of cardiovascular diseases (CVDs), particularly heart failure and ischaemic heart disease (IHD), suggests a study.
Post-PCI bivalirudin infusion reduces death, bleeding vs heparin
Roshini Claire Anthony, 2 days ago

Patients with ST-elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PCI) have a reduced risk of all-cause death or BARC* type 3–5 bleeding when they receive a bolus plus post-PCI high-dose infusion of bivalirudin compared with heparin monotherapy, results of the BRIGHT**-4 trial showed.

Subcutaneous ICDs reduce complications without compromising shock effectiveness
3 days ago
Implantation of subcutaneous implantable cardioverter defibrillators (S-ICDs) results in fewer perioperative, lead-related complications without offsetting the effectiveness of ICD shocks, reveals a study. However, S-ICDs lead to more early postoperative pain and inappropriate shocks.
ADHD medication use carries no excess risk of cardiovascular diseases
3 days ago
Users of attention-deficit/hyperactivity disorder (ADHD) medications across age groups do not appear to be at increased risk of cardiovascular diseases (CVDs), although a modest risk increase of cardiac arrest or tachyarrhythmias could not be ruled out, according to the results of a meta-analysis.
Maximum home BP predicts cardiovascular outcomes in T2D patients
4 days ago
In patients with type 2 diabetes (T2D), maximum home blood pressure (BP) may be used as a potential marker of subsequent cardiovascular events, suggests a retrospective cohort study.
Special Reports
Product Highlight - Amnoz
30 Nov 2022
Amlodipine 5 mg and 10 mg tab
Product Highlight - Cruzor
30 Nov 2022
Irbesartan 300 mg FC tab
Product Highlight - Roxatin
30 Nov 2022
Rosuvastatin 10 mg and 20 mg FC tab
Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF
Elvira Manzano, 04 Oct 2022
The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.
Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum
06 Jun 2022

Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).

Early and consistent: Breakthrough results in HFpEF similar to HFrEF
14 Jan 2022
HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.
EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF
18 Nov 2021
Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.
Conference Reports
Post-PCI bivalirudin infusion reduces death, bleeding vs heparin
Roshini Claire Anthony, 04 Dec 2022

Patients with ST-elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PCI) have a reduced risk of all-cause death or BARC* type 3–5 bleeding when they receive a bolus plus post-PCI high-dose infusion of bivalirudin compared with heparin monotherapy, results of the BRIGHT**-4 trial showed.

IV iron cuts risk of HF rehospitalization, CV death in ambulatory HFrEF patients
Audrey Abella, 02 Dec 2022
In a broad range of patients with HFrEF* and iron deficiency, the administration of IV ferric derisomaltose (FDI) was associated with a lower risk of recurrent hospitalization for heart failure (HHF) and cardiovascular (CV) death compared with standard of care (SoC), findings from the IRONMAN** trial have shown.
Chinese herbal med cuts MACCE in STEMI, but questions remain
Elvira Manzano, 01 Dec 2022
Tongxinluo, added to guideline-directed therapy, improves outcomes in patients with acute ST-segment elevation myocardial infarction (STEMI) in the large, multicentre CTS-AMI* study. But experts are clamouring for more evidence of efficacy.
CT angiography may increase potential recipients of EVT for acute ischaemic stroke
Roshini Claire Anthony, 27 Nov 2022

Using collateral flow findings, as seen on computed tomographic (CT) angiography, may widen the population who can undergo late endovascular treatment (EVT) for acute ischaemic stroke (AIS), according to findings of the MR CLEAN-LATE trial.

No CV benefits with cooler dialysate
Elvira Manzano, 27 Nov 2022
The use of a cooler dialysate during maintenance haemodialysis does not offer cardiovascular (CV) benefits to patients in the MyTEMP trial.
Lower all-cause death, fewer HF events with empagliflozin in acute HF
Roshini Claire Anthony, 25 Nov 2022

Patients hospitalized with acute heart failure (HF) have a reduced risk of subsequent HF events or all-cause mortality if treated with once-daily empagliflozin while in hospital, according to results of the EMPULSE trial presented at HFSA 2022.

Intensive BP-lowering a no-go after reperfusion in ischaemic stroke
Roshini Claire Anthony, 14 Nov 2022

An intensive blood pressure target (<120 mm Hg) should be avoided in patients who have undergone endovascular thrombectomy for acute ischaemic stroke (AIS) for large-vessel occlusion (LVO), results of the phase III ENCHANTED2/MT* trial showed.